Journal of Reproductive Immunology
Volume 85, Issue 1 , Pages 47-50 , May 2010

Cord blood as a source of non-senescent lymphocytes for tumor immunotherapy

Received 8 July 2009 ,Revised 28 January 2010 ,Accepted 2 February 2010.

References 

  1. Azuma H, Yamada Y, Shibuya-Fujiwara N, Yamaguchi M, Murahashi H, Fujihara M. Functional evaluation of ex vivo expanded cord blood lymphocytes: possible use for adoptive cellular immunotherapy. Exp. Hematol. 2002;30:346–351
  2. Ben-Porath I, Weinberg RA. When cells get stressed: an integrative view of cellular senescence. J. Clin. Invest. 2004;113:8–13
  3. Beziat V, Nguyen S, Lapusan S, Hervier B, Dhedin N, Bories D, et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia. 2009;23:721–728
  4. Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin. Immunol. 2008;127:286–297
  5. Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J. Acquir. Immune Defic. Syndr. 2009;50:137–147
  6. Cohen Y, Nagler A. Umbilical cord blood transplantation—how, when and for whom?. Blood Rev. 2004;18:167–179
  7. Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, Champagne MA, et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr. Res. 2005;57(5 Pt 1):649–655
  8. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005;23:2346–2357
  9. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004;22:329–360
  10. Effros RB, Dagarag M, Spaulding C, Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol. Rev. 2005;205:147–157
  11. Eggermont AM. Therapeutic vaccines in solid tumours: can they be harmful?. Eur. J. Cancer. 2009;45:2087–2090
  12. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, et al. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958–1967
  13. Haynes L, Maue AC. Effects of aging on T cell function. Curr. Opin. Immunol. 2009;21:414–417
  14. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  15. Iancu EM, Speiser DE, Rufer N. Assessing ageing of individual T lymphocytes: mission impossible?. Mech. Ageing Dev. 2008;129:67–78
  16. Kadereit S, Mohammad SF, Miller RE, Woods KD, Listrom CD, McKinnon K, et al. Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. Blood. 1999;94:3101–3107
  17. Karanikas, V., Zamanakou, M., Soukou, F., Kerenidi, T., Gourgoulianis, K.I., Germenis, A.E., 2010. Frequency and function of naturally occurring cytolytic CD8+ T cell precursors against multiple tumor antigens in lung cancer patients and healthy individuals. Immunol. Cell Biol., Epub ahead of print.
  18. Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, et al. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Cancer Res. 2006;66:11447–11454
  19. Koch S, Solana R, Dela Rosa O, Pawelec G. Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech. Ageing Dev. 2006;127:538–543
  20. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat. Immunol. 2004;5:133–139
  21. Lundqvist A, Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J. Immunother. 2005;28:281–288
  22. Maue AC, Yager EJ, Swain SL, Woodland DL, Blackman MA, Haynes L. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol. 2009;30:301–305
  23. Mommaas B, Stegehuis-Kamp JA, van Halteren AG, Kester M, Enczmann J, Wernet P, et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood. 2005;105:1823–1827
  24. Mosley RL, Koker MM, Miller RA. Idiosyncratic alterations of TCR size distributions affecting both CD4 and CD8 T cell subsets in aging mice. Cell Immunol. 1998;189:10–18
  25. Nikolich-Žugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat. Rev. Immunol. 2008;8:512–522
  26. Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood. 2006;108:1770–1773
  27. Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstein B, Wikby A. Is immunosenescence infectious?. Trends Immunol. 2004;25:406–410
  28. Pawelec G, Koch S, Griesemann H, Rehbein A, Hähnel K, Gouttefangeas C. Immunosenescence, suppression and tumour progression. Cancer Immunol. Immunother. 2006;55:981–986
  29. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004;10:909–915
  30. Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine. 2000;18:1613–1620
  31. Sun Q, Burton RL, Pollok KE, Emanuel DJ, Lucas KG. CD4+ Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol. 1999;195:81–88
  32. Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 2004;10:7799–7811
  33. Walter S, Bioley G, Bühring HJ, Koch S, Wernet D, Zippelius A, et al. High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur. J. Immunol. 2005;35:2876–2885
  34. Wang P, Munger CM, Joshi AD, Pirruccello SJ, Joshi SS. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res. Treat. 2004;83:15–23
  35. Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Lofgren S, et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech. Ageing Dev. 2006;127:695–704
  36. Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 2008;205:711–723
  37. Zou W. Regulatory T cells, tumour immunity, and immunotherapy. Nat. Rev. Immunol. 2006;6:295–307

PII: S0165-0378(10)00039-2

doi: 10.1016/j.jri.2010.02.002

Journal of Reproductive Immunology
Volume 85, Issue 1 , Pages 47-50 , May 2010

Article Tools